Harnessing the bone-seeking ability of Ca(ii)-like metal ions in the treatment of metastatic cancer and resorption disorders
Metal ions are naturally retained by skeletal tissues in living systems because of their high affinity for the hydroxyapatite-like mineral matrix that makes up cortical bone. This is particularly true for metal ions that bear a close resemblance to calcium( ii ) (such as the lanthanides or alkaline...
Saved in:
| Published in | Chemical Society reviews Vol. 45; no. 8; pp. 224 - 231 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
England
21.04.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Summary: | Metal ions are naturally retained by skeletal tissues in living systems because of their high affinity for the hydroxyapatite-like mineral matrix that makes up cortical bone. This is particularly true for metal ions that bear a close resemblance to calcium(
ii
) (such as the lanthanides or alkaline earth metals), and in a few key cases this targeting ability has been exploited in order to develop medicinal agents that are intended to treat bones which have become diseased. In this review, we focus on two areas where this has been particularly effective: first is in the diagnosis and therapy of metastatic bone cancer, in which radioactive metal ions including
99m
Tc,
153
Sm, and
223
Ra are used to image, alleviate, and ablate harmful cancerous legions with good specificity
versus
healthy tissues; second is the use of trivalent lanthanides to treat osteoporosis, an emerging concept which has gathered significance over the last 15 years, and is now entering preclinical trials with carefully designed systems.
In this tutorial review, we explore how a special relationship between metal ions and bones has been exploited to target therapeutic agents. |
|---|---|
| Bibliography: | David Weekes received his undergraduate education at Newcastle University, Newcastle Upon Tyne, UK, where he completed his M.Chem with honours (2011) in Chemistry with studies in French, as part of the European Erasmus exchange program. He completed research projects at both Newcastle University and at the Université de Strasbourg, France, working in a range of disciplines including supramolecular chemistry and polymeric catalyst supports. He began his PhD with Dr Chris Orvig in 2011 researching novel treatments for osteoporosis in the form of lanthanide ions, a challenging multidisciplinary project with collaborations in pharmaceutical sciences and biomaterials. Chris Orvig earned his Hons. BSc from McGill and his PhD as an NSERC of Canada scholar at MIT with the late Alan Davison, FRS. After postdoctoral positions with Kenneth N. Raymond at the University of California, Berkeley, and the late Colin J. L. Lock at McMaster University, he joined the University of British Columbia in 1984, where he is now Professor of Chemistry and Pharmaceutical Sciences. Orvig, a Fellow of the Royal Society of Canada, has received various teaching, research and service awards, and published more than 200 research papers. He is a co-inventor on many issued patents, and a certified ski instructor. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 |
| ISSN: | 0306-0012 1460-4744 |
| DOI: | 10.1039/c5cs00712g |